Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

EQUITY ALERT: Rosen Law Firm Reminds InVivo Therapeutics Holdings Corp. Investors of Important October 6, 2014 Class Action Deadline -- NVIV

NEW YORK, Sept. 26, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds investors that a class action lawsuit has been filed on behalf of all purchasers of the securities of InVivo Therapeutics Holdings Corp. (OTC:NVIV) between April 5, 2013 and August 26, 2013, inclusive (the "Class Period"), seeking remedies under the federal securities laws.

To join the InVivo Therapeutics class action, go to the website at http://rosenlegal.com/cases-355.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action. 

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, InVivo Therapeutics and certain of its officers and directors misstated and/or failed to disclose the time needed to complete the first-in-man clinical study and compile data for the Company's biopolymer scaffolding product to be provided to the United States Food and Drug Administration (FDA). Further, the Company's August 27, 2013 press release revealed that the Company's stated target date for completing the study and providing its data to the FDA would not be met due to condition established by the FDA. The lawsuit claims that when this adverse news entered the market the price of InVivo Therapeutics dropped, damaging investors.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2014. If you wish to join the litigation go to http://rosenlegal.com/cases-355.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm focuses on prosecuting securities class action litigation and actions involving financial fraud. The Rosen Law Firm represents investors throughout the globe.

CONTACT: Laurence Rosen, Esq.
         Phillip Kim, Esq.
         Kevin Chan, Esq.
         The Rosen Law Firm P.A.
         275 Madison Avenue 34th Floor
         New York, New York 10016
         Tel: (212) 686-1060
         Toll Free: 1-866-767-3653
         Fax: (212) 202-3827
         lrosen@rosenlegal.com
         kchan@rosenlegal.com
         pkim@rosenlegal.com
         www.rosenlegal.com


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today